Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Rare VEGF-Driven Ocular Diseases
NCT01908816Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2013
- Primary completion
- Jan 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in choroidal neovascularization (CNV), macular edema, neovascular glaucoma (NVG), proliferative diabetic retinopathy (PDR), sponsored by Novartis. Started Sep 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
choroidal neovascularization (CNV)macular edemaneovascular glaucoma (NVG)proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT01908816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01908816.